EXEL Logo

Exelixis, Inc. (EXEL) 

NASDAQ
Market Cap
$9.93B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
27 of 774
Rank in Industry
23 of 432

Largest Insider Buys in Sector

EXEL Stock Price History Chart

EXEL Stock Performance

About Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, …

Insider Activity of Exelixis, Inc.

Over the last 12 months, insiders at Exelixis, Inc. have bought $15.27M and sold $28.08M worth of Exelixis, Inc. stock.

On average, over the past 5 years, insiders at Exelixis, Inc. have bought $15.27M and sold $25.58M worth of stock each year.

Highest buying activity among insiders over the last 12 months: JOHNSON DAVID EDWARD (director) — $30.54M.

The last purchase of 225,000 shares for transaction amount of $4.67M was made by JOHNSON DAVID EDWARD (director) on 2024‑05‑30.

List of Insider Buy and Sell Transactions, Exelixis, Inc.

2024-11-18SaleEVP, Commercial
41,588
0.0145%
$34.36$1.43M+1.19%
2024-11-05SaleCSO/EVP Disc & Trans Research
96,986
0.0346%
$35.00$3.39M+0.41%
2024-11-01SaleEVP & General Counsel
50,000
0.0175%
$34.13$1.71M+4.07%
2024-11-01Saledirector
30,000
0.0105%
$34.00$1.02M+4.07%
2024-10-30SaleCSO/EVP Disc & Trans Research
1,162
0.0004%
$31.40$36,487+8.48%
2024-10-28SaleEVP & General Counsel
25,000
0.0086%
$28.39$709,750+6.46%
2024-09-23SaleEVP & General Counsel
25,000
0.0088%
$26.38$659,500+9.31%
2024-08-26SaleEVP, General Counsel & Sec
20,000
0.007%
$25.79$515,800+2.91%
2024-08-14Saledirector
8,250
0.0028%
$26.56$219,1200.00%
2024-08-12SaleCSO/EVP Disc & Trans Research
20,883
0.0073%
$27.06$565,094-1.82%
2024-08-09SaleEVP and CFO
125,000
0.0442%
$27.19$3.4M-1.89%
2024-08-08Saledirector
33,725
0.0115%
$26.89$906,865-2.58%
2024-08-07SaleEVP, General Counsel & Sec
80,000
0.0269%
$25.97$2.08M-0.15%
2024-08-07SaleCSO/EVP Disc & Trans Research
95,000
0.0307%
$25.00$2.38M-0.15%
2024-08-07SaleEVP, Commercial
14,000
0.0046%
$25.50$357,000-0.15%
2024-06-04Saledirector
8,287
0.0029%
$22.00$182,314+19.80%
2024-05-30Purchasedirector
225,000
0.0772%
$20.76$4.67M+24.90%
2024-05-28Purchasedirector
200,000
0.0686%
$20.32$4.06M+27.53%
2024-05-21Saledirector
11,686
0.004%
$20.96$244,939+22.80%
2024-05-21Saledirector
27,280
0.0094%
$21.12$576,154+22.80%

Insider Historical Profitability

73.97%
JOHNSON DAVID EDWARDdirector
1525730
0.5343%
$34.7741
PAPADOPOULOS STELIOSdirector
1260578
0.4414%
$34.77211+117.05%
SCANGOS GEORGE Adirector
714717
0.2503%
$34.771243+51.69%
Schwab GiselaPres, Prod Dev & Med Aff & CMO
614078
0.215%
$34.77137+9.5%
WILLSEY LANCE
424415
0.1486%
$34.771212+142.31%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$827.76M11.9834.88M-3.14%-$26.86M0.02
The Vanguard Group$731.35M10.5830.82M-2.69%-$20.2M0.01
Farallon Capital$633.08M9.1626.68M+0.17%+$1.04M4.45
Renaissance Technologies$358.36M5.1815.1M-3.29%-$12.2M0.57
State Street$310.42M4.4913.08M+0.37%+$1.15M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.